Abstract
The rare, chronic, autosomal-recessive lysosomal storage disease Niemann-Pick disease type C1 (NPC1) is characterized by progressively debilitating and ultimately fatal neurological manifestations. There is an urgent need for disease-modifying therapies that address NPC1 neurological pathophysiology, and passage through the blood-brain barrier represents an important consideration for novel NPC1 drugs. Animal investigations of 2-hydroxypropyl-β-cyclodextrins (HPβCD) in NPC1 in mice demonstrated that HPβCD does not cross the blood-brain barrier in significant amounts but suggested a potential for these complex oligosaccharides to moderately impact CNS manifestations when administered subcutaneously or intraperitoneally at very high doses; however, safety concerns regarding pulmonary toxicity were raised. Subsequent NPC1 investigations in cats demonstrated far greater HPβCD efficacy at much lower doses when the drug was administered directly to the CNS. Based on this, a phase 1/2a clinical trial was initiated with intrathecal administration of a specific, wellcharacterized mixture of HPβCD, with a tightly controlled molar substitution specification and a defined molecular “fingerprint” of the different species. The findings were very encouraging and a phase 2b/3 clinical trial has completed enrollment and is underway. In addition, phase 1 clinical studies utilizing high-dose intravenous administration of a different HPβCD are currently recruiting. Independent studies are needed for each product to satisfactorily address questions of safety, efficacy, dosing, and route of administration. The outcomes cannot be assumed to be translatable between HPβCD products and/or routes of administration.
Keywords: 2-hydroxypropyl-β-cyclodextrins, blood-brain barrier, cyclodextrins, intraperitoneal, intrathecal, lysosomal storage disease, neurodegenerative, Niemann-Pick disease type C, subcutaneous.
Current Pharmaceutical Design
Title:2-Hydroxypropyl-β-cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1
Volume: 23 Issue: 40
Author(s): Pericles Calias*
Affiliation:
- Co-Founder and Pharmaceutical Development Consultant, Educational Trainers and Consultants, 39 Swains Pond Ave, Melrose, MA 02176,United States
Keywords: 2-hydroxypropyl-β-cyclodextrins, blood-brain barrier, cyclodextrins, intraperitoneal, intrathecal, lysosomal storage disease, neurodegenerative, Niemann-Pick disease type C, subcutaneous.
Abstract: The rare, chronic, autosomal-recessive lysosomal storage disease Niemann-Pick disease type C1 (NPC1) is characterized by progressively debilitating and ultimately fatal neurological manifestations. There is an urgent need for disease-modifying therapies that address NPC1 neurological pathophysiology, and passage through the blood-brain barrier represents an important consideration for novel NPC1 drugs. Animal investigations of 2-hydroxypropyl-β-cyclodextrins (HPβCD) in NPC1 in mice demonstrated that HPβCD does not cross the blood-brain barrier in significant amounts but suggested a potential for these complex oligosaccharides to moderately impact CNS manifestations when administered subcutaneously or intraperitoneally at very high doses; however, safety concerns regarding pulmonary toxicity were raised. Subsequent NPC1 investigations in cats demonstrated far greater HPβCD efficacy at much lower doses when the drug was administered directly to the CNS. Based on this, a phase 1/2a clinical trial was initiated with intrathecal administration of a specific, wellcharacterized mixture of HPβCD, with a tightly controlled molar substitution specification and a defined molecular “fingerprint” of the different species. The findings were very encouraging and a phase 2b/3 clinical trial has completed enrollment and is underway. In addition, phase 1 clinical studies utilizing high-dose intravenous administration of a different HPβCD are currently recruiting. Independent studies are needed for each product to satisfactorily address questions of safety, efficacy, dosing, and route of administration. The outcomes cannot be assumed to be translatable between HPβCD products and/or routes of administration.
Export Options
About this article
Cite this article as:
Calias Pericles *, 2-Hydroxypropyl-β-cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1, Current Pharmaceutical Design 2017; 23 (40) . https://dx.doi.org/10.2174/1381612823666171019164220
DOI https://dx.doi.org/10.2174/1381612823666171019164220 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
Current Cardiology Reviews Modelling Human Disease with Pluripotent Stem Cells
Current Gene Therapy Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment
Current Vascular Pharmacology Lipid Lowering Agents, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Amiodarone Hepatotoxicity
Current Vascular Pharmacology Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Detection and Transport Mechanisms of Circulating microRNAs in Neurological, Cardiac and Kidney Diseases
Current Medicinal Chemistry A Systematic Review on Levosimendan in Paediatric Patients
Current Vascular Pharmacology Leptin Induces Neuroprotection Neurogenesis and Angiogenesis after Stroke
Current Neurovascular Research The Control of Arterial Hypertension: Epidemiological and Economic Challenge
Current Hypertension Reviews TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Racing of the Biological Pacemaker
Recent Patents on DNA & Gene Sequences New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) Natriuretic Peptides in Heart Failure and Post-Myocardial Infarction
Current Hypertension Reviews Examination of QTc Values in Critically Ill Patients Diagnosed with Delirium and Prescribed Atypical Antipsychotics
Current Drug Safety Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews Hydrogen Sulfide as a New Endogenous Gaseous Transmitter in the Cardiovascular System
Current Vascular Pharmacology Tocotrienols and Cardiovascular Health
Current Pharmaceutical Design Arterial Stiffness and Type 1 Diabetes: The Current State of Knowledge
Current Diabetes Reviews